Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
Texas 87 California 67 Florida 57 New York 50 Michigan 43
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Daiichi Sankyo6 BeOne Medicines5 OncoC4, Inc.3 Eli Lilly and Company3 MOMA Therapeutics2
State
Texas87 California67 Florida57 New York50 Michigan43
All 42 states
Target enrolment
to

Trials with a site in Florida

57 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
A Study of DS5361b in Participants With Advanced Solid Tumors
NCT07182591Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Daiichi Sankyo
Phase 1
192
Florida, Rhode Island, Texas, Virginia
2025-10-02
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785Advanced Solid Tumor
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Florida, Pennsylvania, South Dakota, Texas, Washington
2025-03-18
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610Advanced Cancer, Advanced Solid Tumor
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1
234
Florida, Virginia
2025-02-10
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359Advanced Solid Tumor
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
DrugsYervoy·Ipilimumab·Opdivo·Nivolumab
7 Hills Pharma, LLC
Phase 1/2
126
Colorado, Florida, New Hampshire, Rhode Island, Texas
2024-08-23
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Florida, Utah
2024-06-05
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1
308
California, Colorado, Florida, Maryland, Ohio
2024-04-12
Recruiting
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862Advanced Solid Tumor
DrugOlaparib
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1
210
California, Florida, Hawaii, Illinois, Massachusetts, New York, North Carolina, Ohio
2024-02-22
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Arizona, California, Florida, Missouri, Texas, Washington
2024-01-18
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050Advanced Solid Tumor, Metastatic Solid Tumor
DrugPembrolizumab
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Arizona, California, Colorado, Florida, Illinois, Minnesota, New York, Ohio
2023-10-26
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
DrugHCB101
FBD Biologics Limited
Phase 1
80
Florida, North Carolina, South Carolina, Texas
2023-10-02
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT05765851Advanced Solid Tumor
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 1
108
Florida, Rhode Island, Utah, Virginia
2023-05-30
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
DrugsEribulin·Trastuzumab deruxtecan·Doxorubicin·Keytruda
GI Innovation, Inc.
Phase 1/2
358
Arizona, Florida, Minnesota, New York, Ohio
2023-05-30
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
DrugPYX-201
Pyxis Oncology, Inc
Phase 1
330
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2023-03-14
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Active, closed
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
DrugsModified FOLFIRINOX·Dabrafenib·Pembrolizumab
Immuneering Corporation
Phase 1/2
209
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New York
2022-10-31
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 1/2
1,123
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Michigan, Nevada
2022-07-19
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
NCT05159700Advanced Solid Tumor, Advanced Solid Malignancies
DrugPRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1
39
Colorado, Florida, Ohio, Texas, Virginia
2022-03-31
Active, closed
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476Advanced Solid Tumor, NSCLC
DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed
Cullinan Therapeutics Inc.
Phase 1
440
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina
2021-10-29
Recruiting
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT04890613Advanced Solid Tumor
Senhwa Biosciences, Inc.
Phase 1
52
California, Florida, Massachusetts, New York, Ohio, Pennsylvania
2021-09-08
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
DrugsKeytruda·Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2
115
California, Florida, Georgia, Michigan, Texas
2021-08-27
Recruiting
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166Advanced Solid Tumor, Metastatic Breast Cancer
DrugBTX-A51
Edgewood Oncology Inc.
Phase 1
112
Florida, Ohio, Tennessee, Texas
2021-06-07
Recruiting
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656Advanced Solid Tumor
DrugsCamonsertib·Lunresertib
Debiopharm International SA
Phase 1
464
California, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2021-04-30
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, New York
2020-10-29
Active, closed
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
DrugsDSP107·Atezolizumab
Kahr Medical
Phase 1/2
125
California, Colorado, Florida, Indiana, Kansas, Pennsylvania
2020-10-07
Active, closed
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
DrugsGotistobart·Taxotere·Docetaxel·Keytruda
OncoC4, Inc.
Phase 1/2
733
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky
2020-09-16
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Arizona, Florida, Minnesota, Texas
2020-09-08
Active, closed
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
NCT04145622Advanced Solid Tumor, Malignant Solid Tumor
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
247
Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey, New York, Tennessee
2019-11-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/florida

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Florida that also match the filters currently applied.

How many clinical trials are recruiting in Florida?

44 of the 57 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florida), 57 studies
PhaseStudiesRecruitingShare
Phase 1332557.9%
Phase 1/2231840.4%
Phase 2111.8%

Most active sponsors

Lead sponsors with the most studies (Florida)
Lead sponsorStudiesRecruiting
Daiichi Sankyo64
BeOne Medicines55
Eli Lilly and Company32
OncoC4, Inc.32
DualityBio Inc.21
Exelixis22
MOMA Therapeutics22
7 Hills Pharma, LLC11
Aulos Bioscience, Inc.11
Avenzo Therapeutics, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.